Discovery of D1 dopamine receptor positive allosteric modulators: Characterization of pharmacology and identification of residues that regulate species selectivity

Journal of Pharmacology and Experimental Therapeutics

Volumn 354, Issue 3, 2015, Pages 340-349

  Lewis, Martin A ^a   Hunihan, Lisa ^a   Watson, John ^a   Gentles, Robert G ^a   Hu, Shuanghua ^a   Huang, Yazhong ^a   Bronson, Joanne ^a   Macor, John E ^a   Beno, Brett R ^a   Ferrante, Meredith ^a   Hendricson, Adam ^a   Knox, Ronald J ^a   Molski, Thaddeus F ^a   Kong, Yan ^a   Cvijic, Mary Ellen ^a   Rockwell, Kristin L ^a   Weed, Michael R ^a   Cacace, Angela M ^a   Westphal, Ryan S ^b   Alt, Andrew ^a   Brown, Jeffrey M ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [[REL 6 (BENZO[D][1,3]DIOXOL 5 YL)BICYCLO[4.1.0]HEPTAN 3 YL] 4 (2 BROMO 5 CHLOROBENZYL)PIPERAZINE]; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; REL N (2,6 DICHLORO 3 METHYLPHENYL) 12 METHYL 9,10 DIHYDRO 9,10 ETHANOANTHRACENE 12 CARBOXAMIDE; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; EC50; EMBRYO; FEMALE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; AGONISTS; ANIMAL; CELL CULTURE; CELL LINE; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; HEK293 CELL LINE; MOUSE; SCHIZOPHRENIA;

ALLOSTERIC REGULATION; ANIMALS; CELL LINE; CELLS, CULTURED; CHO CELLS; CRICETULUS; HEK293 CELLS; HUMANS; MICE; RATS; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA;

EID: 84941555410     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.115.224071     Document Type: Article

References (46)

1. Albrecht FE, Drago J, Felder RA, Printz MP, Eisner GM, Robillard JE, Sibley DR, Westphal HJ, and Jose PA (1996) Role of the D1A dopamine receptor in the pathogenesis of genetic hypertension. J Clin Invest 97:2283-2288.
2. Ballesteros JA and Weinstein H (1995) Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci 25:366-428.
3. Blanchet PJ, Fang J, Gillespie M, Sabounjian L, Locke KW, Gammans R, Mouradian MM, and Chase TN (1998) Effects of the full dopamine D1 receptor agonist dihydrexidine in Parkinson's disease. Clin Neuropharmacol 21:339-343.
4. Brozoski TJ, Brown RM, Rosvold HE, and Goldman PS (1979) Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 205:929-932.
5. Cai JX and Arnsten AF (1997) Dose-dependent effects of the dopamine D1 receptor agonists A77636 or SKF81297 on spatial working memory in aged monkeys. J Pharmacol Exp Ther 283:183-189.
6. Capra V, Veltri A, Foglia C, Crimaldi L, Habib A, Parenti M, and Rovati GE (2004) Mutational analysis of the highly conserved ERY motif of the thromboxane A2 receptor: Alternative role in G protein-coupled receptor signaling. Mol Pharmacol 66:880-889.
7. Castner SA and Goldman-Rakic PS (2004) Enhancement of working memory in aged monkeys by a sensitizing regimen of dopamine D1 receptor stimulation. J Neurosci 24:1446-1450.
8. Christopoulos A and Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374.
9. Chung DA, Zuiderweg ER, Fowler CB, Soyer OS, Mosberg HI, and Neubig RR (2002) NMR structure of the second intracellular loop of the alpha 2A adrenergic receptor: Evidence for a novel cytoplasmic helix. Biochemistry 41:3596-3604.
10. Conn PJ, Christopoulos A, and Lindsley CW (2009) Allosteric modulators of GPCRs: A novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 8:41-54.
11. Cornell WD, Cieplak P, Bayly CL, Gould IR, Merz KM Jr, Ferguson DM, Spellmeyer DC, Fox T, Caldwell JW, and Kollman PA (1995) A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J Am Chem Soc 117:5179-5197.
12. Costa E (1991) The Di Mascio Lecture. The allosteric modulation of GABAA receptors. Seventeen years of research. Neuropsychopharmacology 4:225-235.
13. Davis KL, Kahn RS, Ko G, and Davidson M (1991) Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry 148:1474-1486.
14. Ghosh D, Snyder SE, Watts VJ, Mailman RB, and Nichols DE (1996) 9-Dihydroxy-2, 3, 7, 11btetrahydro- 1H-naph[1, 2, 3-de]isoquinoline: A potent full dopamine D1 agonist containing a rigid-b-phenyldopamine pharmacophore. J Med Chem 39: 549-555.
15. Gregory KJ, Nguyen ED, Reiff SD, Squire EF, Stauffer SR, Lindsley CW, Meiler J, and Conn PJ (2013) Probing the metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulator (PAM) binding pocket: discovery of point mutations that engender a "molecular switch" in PAM pharmacology. Mol Pharmacol 83: 991-1006.
16. Green MF, Kern RS, Braff DL, and Mintz J (2000) Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the "right stuff"? Schizophr Bull 26:119-136.
17. Hollon TR, Bek MJ, Lachowicz JE, Ariano MA, Mezey E, Ramachandran R, Wersinger SR, Soares-da-Silva P, Liu ZF, Grinberg A, et al. (2002) Mice lacking D5 dopamine receptors have increased sympathetic tone and are hypertensive. J Neurosci 22: 10801-10810.
18. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, and Simmerling C (2006) Comparison of multiple Amber force fields and development of improved protein backbone parameters. Proteins 65:712-725.
19. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, and Klein ML (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79:926-935.
20. Jorgensen WL, Maxwell DS, and Tirado-Rives J (1996) Development and testing of the OPLS all-atom force field on conformational energetics and properties of organic liquids. J Am Chem Soc 118:11225-11236.
21. Jorgensen WL and Tirado-Rives J (1998) The OPLS [optimized potentials for liquid simulations] potential functions for proteins, energy minimizations for crystals of cyclic peptides and crambin. J Am Chem Soc 110:1657-1666.
22. Keov P, Sexton PM, and Christopoulos A (2011) Allosteric modulation of G proteincoupled receptors: A pharmacological perspective. Neuropharmacology 60:24-35.
23. Kong MMC, Fan T, Varghese G, O'dowd BF, and George SR (2006) Agonist-induced cell surface trafficking of an intracellularly sequestered D1 dopamine receptor homo-oligomer. Mol Pharmacol 70:78-89.
24. Lindorff-Larsen K, Piana S, Palmo K, Maragakis P, Klepeis JL, Dror RO, and Shaw DE (2010) Improved side-chain torsion potentials for the Amber ff99SB protein force field. Proteins 78:1950-1958.
25. Mottola DM, Kilts JD, Lewis MM, Connery HS, Walker QD, Jones SR, Booth RG, Hyslop DK, Piercey M, Wightman RM, et al. (2002) Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther 301:1166-1178.
26. Nakako T, Murai T, Ikejiri M, Ishiyama T, Taiji M, and Ikeda K (2013) Effects of a dopamine D1 agonist on ketamine-induced spatial working memory dysfunction in common marmosets. Behav Brain Res 249:109-115.
27. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, Villa E, Chipot C, Skeel RD, Kalé L, and Schulten K (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26:1781-1802.
28. Pollock NJ, Manelli AM, Hutchins CW, Steffey ME, MacKenzie RG, and Frail DE (1992) Serine mutations in transmembrane V of the dopamine D1 receptor affect ligand interactions and receptor activation. J Biol Chem 267:17780-17786.
29. Puig MV, Antzoulatos EG, and Miller EK (2014) Prefrontal dopamine in associative learning and memory. Neuroscience 282C:217-229.
30. Rascol O, Blin O, Thalamas C, Descombes S, Soubrouillard C, Azulay P, Fabre N, Viallet F, Lafnitzegger K, Wright S, et al. (1999) ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease. Ann Neurol 45:736-741.
31. Rasmussen SGF, Choi H-J, Fung JJ, Pardon E, Casarosa P, Chae PS, Devree BT, Rosenbaum DM, Thian FS, Kobilka TS, et al. (2011) Structure of a nanobodystabilized active state of the b(2) adrenoceptor. Nature 469:175-180.
32. Rosell DR, Zaluda LC, McClure MM, Perez-Rodriguez MM, Strike KS, Barch DM, Harvey PD, Girgis RR, Hazlett EA, Mailman RB, et al. (2015) Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder. Neuropsychopharmacology 40:446-453.
33. Rovati GE, Capra V, and Neubig RR (2007) The highly conserved DRY motif of class A G protein-coupled receptors: beyond the ground state. Mol Pharmacol 71: 959-964.
34. Scheer A, Fanelli F, Costa T, De Benedetti PG, and Cotecchia S (1996) Constitutively active mutants of the alpha 1B-adrenergic receptor: Role of highly conserved polar amino acids in receptor activation. EMBO J 15:3566-3578.
35. Shivakumar D, Williams J, Wu Y, Damm W, Shelley J, and Sherman W (2010) Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field. J Chem Theory Comput 6:1509-1519.
36. Sibley DR and Monsma FJ Jr (1992) Molecular biology of dopamine receptors. Trends Pharmacol Sci 13:61-69.
37. Thompson JD, Higgins DG, and Gibson TJ (1994) CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22: 4673-4680.
38. Tomic M, Seeman P, George SR, and O'Dowd BF (1993) Dopamine D1 receptor mutagenesis: Role of amino acids in agonist and antagonist binding. Biochem Biophys Res Commun 191:1020-1027.
39. Wang J, Wolf RM, Caldwell JW, Kollman PA, and Case DA (2004) Development and testing of a general amber force field. J Comput Chem 25:1157-1174.
40. Wang X, Escano CS, Asico L, Jones JE, Barte A, Lau YS, Jose PA, and Armando I (2013) Upregulation of renal D5 dopamine receptor ameliorates the hypertension in D3 dopamine receptor-deficient mice. Hypertension 62:295-301.
41. Wang ZQ, Felder RA, and Carey RM (1999) Selective inhibition of the renal dopamine subtype D1A receptor induces antinatriuresis in conscious rats. Hypertension 33:504-510.
42. Weiner SJ, Kollman PA, Case DA, Singh UC, Ghio C, Alagona G, Profeta S Jr, and Weiner P (1984) A new force field for molecular mechanical simulation of nucleic acids and proteins. J Am Chem Soc 106:765-784.
43. Williams GV and Castner SA (2006) Under the curve: critical issues for elucidating D1 receptor function in working memory. Neuroscience 139:263-276.
44. Wootten D, Christopoulos A, and Sexton PM (2013) Emerging paradigms in GPCR allostery: implications for drug discovery. Nat Rev Drug Discov 12:630-644.
45. Yang Z, Sibley DR, and Jose PA (2004) D5 dopamine receptor knockout mice and hypertension. J Recept Signal Transduct Res 24:149-164.
46. Zeng C, Zhang M, Asico LD, Eisner GM, and Jose PA (2007) The dopaminergic system in hypertension. Clin Sci (Lond) 112:583-597.